Email UpdatesDAWN 2022 Non-Fatal Overdoses Short Report
This report from the Drug Abuse Warning Network (DAWN) focuses on estimates and characteristics of non-fatal overdoses for emergency department visits from January, 2021–June, 2022.
Overdose
Tools and resources for addressing overdose, in terms of both prevention and intervention.
DAWN Findings from Drug-Related Emergency Department Visits, 2022
This report provides national estimates from the Drug Abuse Warning Network (DAWN) for 2022 data on drug-related emergency department visits, to inform programs to aid in preventing overdose and substance use-related health consequences.
Fentanyl Drug Checking and Screening: Roundtable on Community Perspectives Summary Report
These proceedings summarize the discussion from the harm reduction community roundtable and supplemental individual interviews, inclusive of representatives from national and local harm reduction organizations, state and local government agencies, tribal organizations, and researchers who have experience distributing fentanyl test strips (FTS) or are knowledgeable about FTS specifically or drug checking more generally.
2022 National Drug Control Strategy
This inaugural National Strategy proposes bold, targeted, and consequential actions to bend the curve on overdose deaths in the immediate term and reduce substance use and its damaging consequences in the US over the longer term.
Obstetric Provider Toolkit for Perinatal Mood and Anxiety Disorders and SUD
This toolkit provides tools to both providers and patients for the assessment and management of perinatal mood and anxiety disorders, as well as substance use disorders (SUD).
Fentanyl Drug Checking and Screening: Roundtable on Clinical Perspectives Summary Report
This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.
Food and Drug Administration Overdose Prevention Framework
The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.
Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics — 25 States and the District of Columbia, 2019-2020
This report describes changes in drug overdose death rates from 2019 to 2020, stratified by sex, age group, and race and ethnicity. In addition, it examines differences in circumstances surrounding drug overdose, and assesses differences in overdose death rates by county-level income inequality and availability of mental health treatment providers and providers of medications for opioid use disorder.
State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
These estimated costs of opioid use disorder and fatal opioid overdose and their per capita costs at the state level can assist federal and state decision makers in understanding the magnitude of opioid use disorder and fatal opioid overdose in their jurisdictions.
Provisional Drug Overdose Death Counts
This data visualization presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System.